Detail akcie AdaptimmTher Sp ADR online

Business Summary: Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Adaptimmune Therapeutics PLC - ADR revenues increased 28% to $7.3M. Net loss decreased 2% to $47.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Clinical-stage biopharmaceutical segment loss decrease of 7% to $45.7M. Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.03.